SCHEMBL10116480

SCHEMBL10116480

CC(C)S(=O)(=O)Nc1ccc(C(=O)Nc2ccccc2C(F)(F)F)cc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.59
ALDH1A1 P00352 5/20 0.49
LMNA P02545 2/20 0.49
MAPT P10636 2/20 0.49
ALOX12 P18054 1/20 0.49
CNR2 P34972 1/20 0.47
POLB P06746 2/20 0.47
MAPK1 P28482 1/20 0.47
HPGD P15428 2/20 0.46
MAPK10 P53779 1/20 0.46
GAA P10253 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
MYC P01106 1/20 0.45
MAX P61244 1/20 0.45
PLA2G7 Q13093 1/20 0.45
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10116199 0.84 SMN1; SMN2 (0.60) SMN1; SMN2ALDH1A1LMNAMAPTALOX12
SCHEMBL10116472 0.84 RAB9A (0.56) SMN1; SMN2ALDH1A1LMNAMAPTHPGD
SCHEMBL10116604 0.83 RAB9A (0.41) SMN1; SMN2ALDH1A1LMNAMAPTGAA
SCHEMBL10116572 0.81 TRPV1 (0.62) SMN1; SMN2LMNAMAPTHDAC8HDAC6
SCHEMBL10116659 0.80 MAPT (0.50) LMNAMAPTHPGDHDAC8HTT
SCHEMBL10116628 0.80 KMT2A (0.50) SMN1; SMN2ALDH1A1LMNAMAPTMAPK1
SCHEMBL10116585 0.80 ALDH1A1 (0.53) ALDH1A1LMNAMAPTGAA
SCHEMBL10116458 0.79 GRIA4 (0.60) SMN1; SMN2ALDH1A1LMNAMAPTPOLB
SCHEMBL19997239 0.78 KMT2A (0.54) SMN1; SMN2ALDH1A1LMNAMAPTPOLB
SCHEMBL10116755 0.78 MAPT (0.46) LMNAMAPTHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-8115027-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2012-02-14 US disclosed
US-20110039802-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2011-02-17 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-20100292500-A1 NPY Y5 ANTAGONIST KAWANISHI YASUYUKI 2010-11-18 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7781461-B2 NPY Y5 antagonist KAWANISHI YASUYUKI 2010-08-24 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-7265130-B2 NPY Y5 antagonist SHIONOGI & CO., LTD. (JP) 2007-09-04 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed
US-20070015762-A1 NPY Y5 antagonist KAWANISHI YASUYUKI 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015762-A1 NPY Y5 antagonist NPY5R, NPY1R, NPY2R SMN1; SMN2 2213/4885ALDH1A1 4558/4885LMNA 1925/4885
US-20100292500-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2197/4885ALDH1A1 4599/4885LMNA 2068/4885
US-20110039802-A1 NPY Y5 ANTAGONIST NPY5R, NPY1R, NPY2R SMN1; SMN2 2251/4885ALDH1A1 4517/4885LMNA 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.